Reagents for EBOV ResearchInquiry Basket
Loading ......
Ebola virus disease (EVD) is a severe, often fatal systemic infection in humans and non-human primates caused by viruses of the genus Ebolavirus (family Filoviridae). Since the first documented outbreaks in 1976, filoviruses have caused recurrent epidemics in Central and West Africa.
Zaire ebolavirus (EBOV): The most lethal species, responsible for the devastating 2014–2016 West African epidemic (over 28,000 cases and 11,000 deaths).
Sudan ebolavirus (SUDV): Explodes sporadically, most recently during the 2022–2023 Uganda outbreak, showcasing a critical gap in approved countermeasures.
Bundibugyo ebolavirus (BDBV): A distinct species capable of causing major clinical outbreaks with high mortality.
The pathobiology of EVD involves rapid systemic viral replication, targeted immune evasion, profound vascular dysfunction, and a cytokine storm. Effective vaccination is widely recognized as the single most powerful tool to achieve rapid outbreak control through ring vaccination strategies and to protect high-risk populations, such as healthcare workers.
Fig. 1 Filovirus taxonomy
The primary immunological target for Ebola vaccine development is the viral Glycoprotein (GP), a class I fusion protein expressed on the viral envelope. GP is synthesized as a single polypeptide precursor (GP0) and cleaved by host furin proteases into two distinct disulfide-linked subunits, which assemble as a chalice-shaped homotrimer:
GP1 Subunit (Attachment): Coordinates viral docking to host surface lectins and contains the highly variable Mucin-Like Domain (MLD) and the glycan cap. These domains act as a glycan shield, protecting the highly conserved Receptor Binding Site (RBS) from humoral immune recognition. Following endocytosis into the host cell, endosomal cathepsins (B and L) cleave the MLD and glycan cap, exposing the RBS so it can bind to its intracellular receptor, Niemann-Pick C1 (NPC1).
GP2 Subunit (Fusion): Contains the hydrophobic fusion peptide, heptad repeats, and the transmembrane anchor that physically drive the fusion of the viral envelope with the host endosomal membrane.
The Structural Goal of Vaccinology: To generate highly potent, neutralizing humoral responses, vaccine antigens must display the GP in its native, prefusion trimeric conformation. Eliciting antibodies that target conserved, functionally critical regions—such as the hydrophobic fusion loop or the hidden RBS—is key to achieving cross-reactive, pan-filovirus protection.
Fig. 2 EBOV genome and life cycle
The rapid mobilization of clinical research during the 2014–2016 West African epidemic revolutionized the filovirus vaccine landscape, resulting in the regulatory licensing of two landmark vaccine regimens targeting Zaire ebolavirus:
This single-dose, live-attenuated recombinant vector vaccine utilizes a vesicular stomatitis virus (VSV) backbone where the native VSV envelope gene has been replaced with the GP gene of Zaire ebolavirus.
Efficacy: Demonstrated exceptional protective efficacy (approaching 100% in initial Phase III ring trials in Guinea).
Clinical Role: Because it replicates in the host and stimulates rapid, robust neutralizing antibody responses within days, rVSV-ZEBOV is the primary tool deployed for ring vaccination—immunizing contacts and contacts-of-contacts to form a human firewall around active transmission chains.
A heterologous, two-dose prime-boost vaccine regimen designed to provide durable, long-term immunity.
The Prime: Recombinant adenovirus type 26 expressing EBOV GP (Ad26.ZEBOV).
The Boost (8 weeks later): A non-replicating Modified Vaccinia Ankara (MVA) vector expressing glycoproteins from EBOV, SUDV, and BDBV, alongside Marburg virus nucleoprotein (MVA-BN-Filo).
Clinical Role: Rather than emergency outbreak containment, this approach is optimized to establish long-lasting, immunological memory (comprising both high-titer antibodies and robust CD4+/CD8+ T-cell responses), making it ideal for preventative deployment in high-risk occupational cohorts, such as frontline medical staff and laboratory personnel.
Additionally, the recombinant adenovirus type 5-based vaccine (Ad5-EBOV) has been approved in China. This single-dose vector platform expressing EBOV GP is highly immunogenic, though researchers closely monitor its performance in populations with high pre-existing immunity to the common human adenovirus type 5 vector.
Modern filovirus research leverages a broad array of technological platforms, each striking a unique balance between immunogenicity, ease of production, safety, and operational logistics.
| Platform | Core Mechanism / Notable Candidates | Immunological Strengths | Translational & Technical Challenges | Clinical / Development Status |
| Viral Vectors (Replicating) |
|
|
| Approved (EBOV) / Clinical Phase I/II (SUDV) |
| Viral Vectors (Non-Replicating) |
|
|
| Approved (EBOV) / Clinical Phase I/II (SUDV) |
| Protein Subunits |
|
|
| Clinical Phase I / Preclinical |
| mRNA Vaccines |
|
|
| Active Phase I Clinical Trials / Preclinical |
| DNA Vaccines |
|
|
| Preclinical / Historical Clinical Studies |
| Virus-Like Particles (VLPs) |
|
|
| Preclinical |
EBOV, SUDV, and BDBV exhibit up to 30–40% sequence divergence in their GP genes. Consequently, antibodies elicited by EBOV vaccines rarely cross-neutralize SUDV or BDBV. Resolving this requires multivalent formulations or computational design of mosaic immunogens targeting conserved fusion loop epitopes.
While GP-specific IgG titers (ELISA) and pseudovirus neutralizing antibody titers are established surrogates, true protection involves a complex synergy between:
Functional Antibodies: Antibody-dependent cellular cytotoxicity (ADCC) and complement deposition.
Cellular Immunity: CD4+ and CD8+ T-cell memory responses. Defining a universally standardized threshold of protection remains an active regulatory challenge under FDA's "Animal Rule."
In vitro studies show that certain non-neutralizing antibodies binding to specific regions of the GP can facilitate viral entry into Fcγ-receptor-bearing immune cells. Next-generation antigen design must selectively mask or eliminate these ADE-mediating epitopes to guarantee safety.
Because Ebola outbreaks are sporadic and unpredictable, conducting traditional Phase III efficacy trials during an active outbreak is logistically complex and ethically delicate. Researchers must increasingly rely on immunobridging strategies in Non-Human Primate (NHP) models.
Developing, optimizing, and verifying the potency of Ebola vaccine candidates requires an integrated suite of advanced, high-precision bioanalytical testing assays:
Humoral Evaluation: Total IgG levels targeting the GP are quantified using standardized Enzyme-Linked Immunosorbent Assays (ELISA). While binding titers are informative, characterizing antibody quality—including subclass distribution, epitope specificity, binding affinity, and functional neutralization capacity—is essential to verify the protective potential of the humoral response.
Cellular Analysis: T-cell responses are critical for clearing virus-infected cells and supporting long-term humoral memory. Standard assays include Enzyme-Linked Immunospot (ELISpot) to detect interferon-gamma (IFN-γ) secreting cells, and multi-color flow cytometry combined with intracellular cytokine staining (ICS) to profile polyfunctional CD4+ and CD8+ T-cell populations.
Animal Challenge Studies: Non-human primates (NHPs), particularly rhesus and cynomolgus macaques, serve as the gold-standard animal models because they replicate human EVD pathology (coagulopathy, shock, and multi-organ failure) with high fidelity. Vaccine efficacy is validated by challenging immunized animals with wild-type virus in Biosafety Level 4 (BSL-4) containment facilities, assessing survival, clinical scores, and systemic viral load reduction.
The future of filovirus protection lies in moving away from reactive, single-species monovalent vaccines toward proactive, broad-spectrum immunization strategies.
The most direct approach to broadening protection is the development of multivalent formulations. For example, combining EBOV, SUDV, and BDBV glycoproteins within a single vaccine delivery vehicle (such as an mRNA-LNP or a multivalent viral vector) allows the immune system to generate distinct, protective antibody pools against each target simultaneously.
Rather than physically mixing three different glycoproteins, structural biologists and bioinformaticians are using computational tools to design mosaic or consensus GP antigens. By aligning the GP sequences of diverse filoviruses and identifying highly conserved structural patches, researchers can engineer synthetic antigens that direct the immune response specifically toward cross-reactive, highly neutralizing epitopes.
In addition to targeting the highly variable outer domains of GP, researchers are exploring highly conserved targets across the entire Filoviridae family, including Marburg virus (MARV). By co-targeting the highly conserved hydrophobic fusion loop of the GP2 subunit and integrating secondary structural proteins like the Nucleoprotein (NP) or VP40 matrix protein—which contain highly conserved T-cell epitopes—next-generation vaccines aim to establish a broad base of T-cell and non-neutralizing antibody-mediated immunity capable of neutralizing any emerging filovirus threat.
The translation of next-generation vaccine concepts from the laboratory bench to clinical trials depends heavily on the availability of high-quality, standardized, and structurally verified research reagents:
Conformationally Correct Recombinant Proteins: Standardized, trimeric recombinant GP antigens (both full-length and mucin-domain deleted versions) are essential for plate-coating in high-throughput ELISA screenings and for structural validation.
Validated Reference Antibodies: Well-characterized monoclonal antibodies (such as KZ52, 114, or mAb114-like references) serve as vital positive controls in neutralization assays, positive markers for antigen conformation validation, and standards for epitope-mapping competitions.
Viral Core Proteins: High-purity Nucleoprotein (NP) and Matrix Protein (VP40) reagents are necessary for the development of western blot assays, multiplexed bead-based serology arrays, and for the structural assembly of recombinant virus-like particles (VLPs).
The landscape of Ebola vaccine development has transitioned from a state of emergency reaction to structural, rational vaccine design. While live-replicating vectors like rVSV-ZEBOV have successfully subdued recent West African outbreaks, the future of filovirus global preparedness lies in multivalent platforms (such as mRNA and nanoparticle arrays) capable of neutralizing EBOV, SUDV, and BDBV simultaneously. Sustained innovation in structural biology, standardized pseudoviral evaluation assays, and stable formulation engineering will collectively ensure the world is equipped to preempt the next filovirus epidemic.
| Cat. No. | Product Name | Species Reactivity | Sample | |
| DEIA-EBOV-1 | Mouse Anti-Zaire Ebola virus Nucleoprotein (NP) IgG ELISA Kit, 96 tests | Mouse | Serum, plasma or other biological fluids | Inquiry |
| DEIA-EBOV-2 | Human Anti-Zaire Ebola virus Nucleoprotein (NP) IgG ELISA Kit, 96 tests | Human | Serum, Plasma or other biological fluids | Inquiry |
| DEIA-EBOV-3 | Human Anti-Zaire Ebola virus glycoprotein (GP) IgM ELISA Kit, 96 tests | Human | Serum, Plasma | Inquiry |
Loading ......
